Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.
Videos
Binod Dhakal, MD, discusses the BOSTON trial of selinexor combination therapy in patients with relapsed/refractory multiple myeloma.
Hardeep Phull, MD, explains the impact that telehealth has had for oncologists and patients.
A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.
A panelist discusses how this is an exciting time for pancreatic cancer treatment with the development of RAS inhibitors targeting KRAS mutations (present in approximately 90% of patients with metastatic pancreatic cancer, including G12D, G12V, and G12C variants), which have shown impressive response rates in later-line settings and are being evaluated in frontline trials, before concluding the Targeted Oncology discussion on the metastatic pancreatic adenocarcinoma treatment landscape.
A recent trial reveals cemiplimab significantly reduces recurrence in high-risk cutaneous squamous cell carcinoma, setting a new standard for adjuvant treatment.
Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin) represents a reasonable treatment option for patients with excellent performance status and locally advanced pancreatic adenocarcinoma, requiring close monitoring and proactive toxicity management to maximize outcomes.
Panelist discusses how post hoc analyses of the NAPOLI-3 trial revealed that dose reductions for toxicity management do not adversely affect overall survival and that UGT1A1 mutations do not significantly impact treatment tolerability with nanoliposomal irinotecan.
Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.
Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.
George Mulligan, PhD, highlights the importance of clinical trials and innovative research in advancing myeloma treatment and pursuing potential cures.
Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.
George Mulligan, PhD, explores the impact of linvoseltamab's FDA approval on multiple myeloma treatment, highlighting innovative bispecific antibodies and patient-centered strategies.
Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.
A panelist discusses how proactive adverse event management is crucial for patients with metastatic pancreatic cancer, including using every-2-week scheduling and primary granulocyte colony-stimulating factor (G-CSF) support to reduce myelosuppression, providing extensive patient counseling about diet, hydration, and early antidiarrheal use for liposomal irinotecan-related diarrhea, and closely monitoring for cumulative neuropathy with consideration of oxaliplatin discontinuation by 3 to 4 months if responding to prevent limitations on future therapy options.
A panelist discusses how treating metastatic pancreatic cancer requires a multidisciplinary approach with early palliative care and dietitian involvement, emphasizing that for patients with good performance status, 3-drug regimens like NALIRIFOX or modified FOLFIRINOX can provide clinical responses and quality-of-life improvements even in high disease burden cases, whereas frail patients benefit from gemcitabine plus nab-paclitaxel administered every 2 weeks, and notes that age alone should not exclude patients from 3-drug regimens as the NAPOLI-3 trial included patients aged up to 85 years.
Explore the disparities in treatment patterns for myelodysplastic syndromes and discover solutions to improve patient outcomes in community settings.
Study reveals alarming treatment gaps in high-risk Myelodysplastic Syndromes, highlighting disparities and adherence issues that impact patient outcomes.
A recent study uncovers disparities in treatment patterns for myelodysplastic syndromes, revealing critical insights into patient outcomes and care access.
Pierre Gholam, MD, examines the limited trial data on treatment for patients with hepatocellular carcinoma (HCC) with worse Child-Pugh scores.
Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, oxaliplatin) management requires careful attention to cytopenia prevention through growth factor use and aggressive diarrhea management with patient education and antidiarrheal medications.
Panelist discusses how the development of nanoliposomal irinotecan led to the NAPOLI-1 trial showing a survival benefit in second-line treatment and subsequently the NAPOLI-3 trial demonstrating the superiority of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, oxaliplatin) over gemcitabine/nab-paclitaxel in first-line metastatic disease.
Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.
Binod Dhakal, MD, discusses using a variety of combination therapies as bridging or later-line options for patients with relapsed myeloma.
Overview of Clinical Trial Data A panelist discusses how first-line treatment recommendations are based on 3 pivotal phase 3 randomized trials: PRODIGE 4 (which established FOLFIRINOX superiority over gemcitabine with 11.1 vs 6.8 months overall survival despite higher toxicity), MPACT (showing gemcitabine plus nab-paclitaxel benefit over single-agent gemcitabine with 8.5 vs 6.7 months survival), and the recent NAPOLI-3 (demonstrating NALIRIFOX superiority over gemcitabine plus nab-paclitaxel with 11.1 vs 9.2 months overall survival in over 750 patients across 180 sites).
A panelist discusses how treatment selection for metastatic pancreatic adenocarcinoma involves evaluating multiple factors including genetic and somatic mutations (particularly homologous recombination deficiency [HRD] alterations like BRCA1/2 and PALB2, which favor platinum-based regimens), patient age and performance status, liver function status, and drug metabolism genotype testing such as dihydropyrimidine dehydrogenase (DPD) deficiency screening to avoid severe 5-FU toxicity in rare cases of homozygous variants.
A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict patient outcomes.
An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.
Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of Chief Insights in Oncology.
A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating CAR T toxicities.